Immune responses to hepatitis B surface antigen following epidermal powder immunization

Immunology and Cell Biology

Volumn 81, Issue 1, 2003, Pages 52-58

  Osorio, Jorge E ^a   Zuleger, Cindy L ^a   Burger, Melissa ^a   Chu, Qili ^a   Payne, Lendon G ^a   Chen, Dexiang ^a  

^a PowderJect Vaccines Inc   (United States)

Author keywords

Alum; CpG; Cytokines; Hepatitis B; Hepatitis B surface antigen; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; DNA; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; EPIDERMIS; FEMALE; HELPER CELL; HEPATITIS B; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INJECTION; LANGERHANS CELL; MOUSE; NONHUMAN; POWDER;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CPG ISLANDS; CYTOKINES; DNA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPIDERMIS; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; VACCINES;

ANIMALIA; INFLUENZA VIRUS;

EID: 0037326879     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2003.01134.x     Document Type: Article

References (27)

1. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995; 13: S47-9.
2. Grob P, Hallauer J, Kane M et al. Hepatitis B: a serious public health threat. Viral Hepatitis Prevention Board. Vaccine 1998; 16: S1-2.
3. Coleman PJ, McQuillan GM, Moyer LA et al. Incidence of hepatitis B virus infection in the United States, 1976-94: estimates from the National Health and Nutrition Examination Surveys. J. Infect. Dis. 1998; 178: 954-9.
4. Chen HL, Chang MH, Ni YH et al. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. Jama 1996; 276: 906-8.
5. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semi. Immunopathol. 1995; 17: 261-81.
6. Kane M. Epidemiology of hepatitis B infection in North America. Vaccine 1995; 13: S16-7.
7. Mahoney FJ, Stewart K, Hu H et al. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch. Intern. Med. 1997; 157: 2601-5.
8. Maynard JE, Kane MA, Hadler SC. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization. Rev. Infec. Dis. 1989; 11: S574-8.
9. Stephenne J. Contribution to hepatitis B prevention. Vaccine 1992; 10: 900-3.
10. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am. J. Med. 1989; 87: 36S-40S.
11. Thoelen S. An overview on a novel adjuvanted prophylactic hepatitis B vaccine. Acta Gastroenterol. Belg. 2000; 63: 185-6.
12. Authier FJ, Cherin P, Creange A et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001; 124: 974-83.
13. Simonsen L, Kane A, Lloyd J et al. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Organ. 1999; 77: 789-800.
14. Chen D, Endres RL, Erickson CA et al. Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice. Nat. Med. 2000; 6: 1187-90.
15. Chen D, Weis KF, Chu Q et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. 2001; 75: 11 630-40.
16. Chen D, Periwal SB, Larrivee K et al. Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J. Virol. 2001; 75: 7956-65.
17. Chen D, Erickson CA, Endres RL et al. Adjuvantation of epidermal powder immunization. Vaccine 2001; 19: 2908-17.
18. Chen D, Endres RL, Erickson CA, Maa YF, Payne LG. Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity. Vaccine 2002; 20: 2671-9.
19. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 1996; 98: 1119-29.
20. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 1997; 94: 10 833-47.
21. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl Acad. Sci. USA 1999; 96: 9305-10.
22. Davis HL, Weeratna R, Waldschmidt TJ et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 1998; 160: 870-6.
23. McCutcheon M, Wehner N, Wensky A et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Meth. 1997; 210: 149-66.
24. Behboudi S, Chao D, Klenerman P, Austyn J. The effects of DNA containing CpG motif on dendritic cells. Immunology 2000; 99: 361-6.
25. Park Y, Lee SW, Sung YC. Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3′-OH kinase pathway. J. Immunol. 2002; 168: 5-8.
26. Davis HL. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt. Sinai J. Med. 1999; 66: 84-90.
27. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect. Dis. 2002; 2: 43-50.